Pulmonx Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Pulmonx Corporation's estimated annual revenue is currently $44.5M per year.
- Pulmonx Corporation received $20.0M in venture funding in September 2014.
- Pulmonx Corporation's estimated revenue per employee is $171,308
- Pulmonx Corporation's total funding is $276.9M.
- Pulmonx Corporation's current valuation is $1B. (January 2022)
Employee Data
- Pulmonx Corporation has 260 Employees.
- Pulmonx Corporation grew their employee count by 8% last year.
Pulmonx Corporation's People
Name | Title | Email/Phone |
---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Area VP Sales, EMEA | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | VP, Finance & Administration | Reveal Email/Phone |
5 | SVP & General Manager, Europe Middle-East & Africa | Reveal Email/Phone |
6 | VP, Patient Access | Reveal Email/Phone |
7 | VP, Marketing | Reveal Email/Phone |
8 | VP Clinical Affairs | Reveal Email/Phone |
9 | VP, Corporate Controller | Reveal Email/Phone |
10 | VP Finance & Administration, US | Reveal Email/Phone |
Pulmonx Corporation Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Pulmonx Corporation?
Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. The Company's first commercial products address emphysema, a form of COPD (chronic obstructive pulmonary disease) and the largest unmet medical need in Pulmonology. With emphysema, breathing becomes increasingly more difficult as the disease progresses. Today in the U.S., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. Pulmonx has developed the Zephyr Endobronchial Valve (EBV) Therapy, a non-surgical, investigational approach to treating emphysema. The minimally invasive Zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. No surgery is involved in the simple, one-hour procedure. More than 25,000 Zephyr valves have been implanted outside the U.S. in the last 10 years. Clinical studies in Europe have shown that the majority of qualified patients who have the procedure see a significant improvement in lung function, exercise tolerance and quality of life. In the United States, Pulmonx is conducting the LIBERATE Clinical Study to evaluate the safety and effectiveness of the Zephyr valve in patients with severe emphysema. Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. The company does not yet market or sell its products in the United States. CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.
keywords:Biotechnology$276.9M
Total Funding
260
Number of Employees
$44.5M
Revenue (est)
8%
Employee Growth %
$1B
Valuation
N/A
Accelerator
Pulmonx Corporation News
According to Zacks, Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive...
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx's Zephyr® Endobronchial...
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally...
KNOXVILLE, Tenn., Jan. 28, 2021 /PRNewswire/ -- JTV®, the national jewelry retailer and broadcast network, is excited to announce its third annual Catch Your Breath® campaign, in partnership with Respiratory Health Association® (RHA) and co-sponsor Pulmonx® Corporation, to support the fight ag ...
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor. The financi ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $101.3M | 267 | -21% | $162M |
#2 | $43M | 276 | 47% | $350M |
#3 | $61.2M | 279 | -3% | $96.3M |
#4 | $7.5M | 280 | 51% | N/A |
#5 | $42.9M | 285 | 18% | $45M |
Pulmonx Corporation Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2007-03-22 | $18.5M | B1 | Article | |
2007-05-08 | $20.4M | B-1 | De Novo Ventures, Latterell Venture Partners | Article |
2008-08-18 | $3.0M | Undisclosed | Article | |
2010-01-20 | $11.5M | Undisclosed | De Novo Ventures, Latterell Venture Partners | Article |
2010-02-23 | $32.0M | Undisclosed | Article | |
2014-04-02 | $10.0M | Undisclosed | Article | |
2014-09-18 | $20.0M | Undisclosed | Oxford Finance LLC | Article |